NewcelX Ltd.
Business
NewcelX Ltd. is a clinical-stage biopharmaceutical company developing therapies for rare and complex central nervous system (CNS) disorders. It offers lead product candidates Quilience and Nolazol—both mazindol-based, once-daily controlled‑release formulations—and a discovery pipeline including NLS‑4 and a Dual Orexin Receptor Agonist platform licensed from Aexon. Its key business segments include small‑molecule CNS therapeutics and, following a merger agreement, a cell‑therapy franchise via Kadimastem. NewcelX distributes and develops products through clinical trials, named‑patient/compassionate‑use programs, regulatory filings and third‑party manufacturing and licensing arrangements across the U.S., Europe and other international markets.
Summary from filing dated 2025-05-16
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-8.30M |
| Total assets | $11.45M |
| Total liabilities | $4.20M |
| Stockholders' equity | $7.25M |
| Operating cash flow | $-2.77M |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is NewcelX Ltd.'s CIK number?
NewcelX Ltd.'s SEC CIK number is 0001783036 (1783036). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find NewcelX Ltd.'s SEC filings?
All of NewcelX Ltd.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.